BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 8203785)

  • 1. Techniques used to evaluate the cutaneous microcirculation: application of photoplethysmography to the assessment of a phlebotropic agent in the treatment of leg ulcers.
    Guillot B
    Angiology; 1994 Jun; 45(6 Pt 2):542-8. PubMed ID: 8203785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin perfusion pressure in leg ulcers assessed by photoplethysmography.
    Guillot B; Dandurand M; Guilhou JJ
    Int Angiol; 1988; 7(2 Suppl):33-4. PubMed ID: 3183454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
    Geroulakos G; Nicolaides AN
    Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The principles of action and use of phlebotropic agents].
    Kharkevich DA
    Klin Med (Mosk); 2004; 82(11):4-10. PubMed ID: 15656390
    [No Abstract]   [Full Text] [Related]  

  • 5. Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency.
    Balas P; Pagratis N
    Int Angiol; 1989; 8(4 Suppl):51-2. PubMed ID: 2632650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
    Struckmann JR; Nicolaides AN
    Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
    Hnátek L
    Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency.
    Allegra C; Bartolo M; Carioti B; Cassiani D
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():50-4. PubMed ID: 8748890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Pycnogenol on the Healing of Venous Ulcers.
    Toledo RR; Santos MERC; Schnaider TB
    Ann Vasc Surg; 2017 Jan; 38():212-219. PubMed ID: 27521821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)].
    Iablokov EG; Bogachev VIu; Domoradskaia AI
    Ter Arkh; 1996; 68(10):80-1. PubMed ID: 9026954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency.
    Belcaro G; Cesarone MR; de Sanctis MT; Incandela L; Laurora G; Février B; Wargon C; De Gregoris P
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():45-9. PubMed ID: 8748889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg--repercussions of venous insufficiency on everyday life.
    Launois R
    Angiology; 1994 Jun; 45(6 Pt 2):495-504. PubMed ID: 8203779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
    Ramelet AA
    Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From skin disorders to venous leg ulcers: pathophysiology and efficacy of Daflon 500 mg in ulcer healing.
    Coleridge Smith PD
    Angiology; 2003; 54 Suppl 1():S45-50. PubMed ID: 12934756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
    Guilhou JJ; Dereure O; Marzin L; Ouvry P; Zuccarelli F; Debure C; Van Landuyt H; Gillet-Terver MN; Guillot B; Levesque H; Mignot J; Pillion G; Février B; Dubeaux D
    Angiology; 1997 Jan; 48(1):77-85. PubMed ID: 8995348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical experiences with a vasoprotective drug in the treatment of venous problems of the lower limbs].
    De Caprio M; Vinci L; Giumetti D; Colitta G
    Clin Ter; 1982 Jun; 101(5):497-508. PubMed ID: 6897029
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency.
    Roztocil K; Stvrtinová V; Strejcek J
    Int Angiol; 2003 Mar; 22(1):24-31. PubMed ID: 12771852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the therapeutic effect of a phlebotropic drug with a new noninvasive method: rheography by reflected light].
    Tumino G; Berni A; Tromba L; Marignetti L
    Clin Ter; 1987 Aug; 122(3):189-94. PubMed ID: 2973911
    [No Abstract]   [Full Text] [Related]  

  • 20. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.